Literature DB >> 11594752

Development and characterization of an antisense-mediated prepackaging cell line for adeno-associated virus vector production.

T Okada1, H Mizukami, M Urabe, T Nomoto, T Matsushita, Y Hanazono, A Kume, K Tobita, K Ozawa.   

Abstract

One of the limitations of recombinant adeno-associated virus (rAAV) vector systems for gene therapy applications has been the difficulty in producing the vector in sufficient quantity for adequate evaluation. Since the AAV Rep proteins are cytotoxic, it is not easy to establish stable cell lines that express them constitutively. We describe a novel 293-derived prepackaging cell line which constitutively expresses the antisense rep/cap driven by a loxP-flanked CMV promoter. This cell line was converted into a packaging cell line expressing Rep/Cap for rAAV vector production through adenovirus-mediated introduction of a Cre recombinase gene. Without the introduction of the Cre recombinase gene, the cell line was shown to produce neither Rep nor Cap. rAAV vector was produced (1 x 10(9) genome copies/3.5-cm dish) 4 days after the transduction with Cre-expression adenovirus vector together with transfection of AAV vector plasmid. We further showed that the addition of Cap-expression adenovirus vector caused a 10-fold increase in the yield of rAAV vector. This system is also capable of producing rAAV as a transfection-free system by using a small amount of rAAV instead of vector plasmid. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594752     DOI: 10.1006/bbrc.2001.5730

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Evaluation of a Serum-free Medium for the Production of rAAV-2 using HeLa Derived Producer Cells.

Authors:  C Jenny; E Toublanc; O Danos; O-W Merten
Journal:  Cytotechnology       Date:  2005-09       Impact factor: 2.058

3.  A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines.

Authors:  Chunping Qiao; Bing Wang; Xiaodong Zhu; Juan Li; Xiao Xiao
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Separate control of Rep and Cap expression using mutant and wild-type loxP sequences and improved packaging system for adeno-associated virus vector production.

Authors:  Hiroaki Mizukami; Takashi Okada; Yoji Ogasawara; Takashi Matsushita; Masashi Urabe; Akihiro Kume; Keiya Ozawa
Journal:  Mol Biotechnol       Date:  2004-05       Impact factor: 2.695

Review 5.  Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence.

Authors:  Arianna Manini; Elena Abati; Andi Nuredini; Stefania Corti; Giacomo Pietro Comi
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003

6.  Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy.

Authors:  Takashi Okada; Shin'ichi Takeda
Journal:  Pharmaceuticals (Basel)       Date:  2013-06-27

7.  Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery.

Authors:  Parminder Singh Chahal; Erica Schulze; Rosa Tran; Johnny Montes; Amine A Kamen
Journal:  J Virol Methods       Date:  2013-11-13       Impact factor: 2.014

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.